RESOMER LR 704 S Bioresorbable L/DL-Lactide Medical Grade is a non-sterile thermoplastic polyester supplied by Evonik Health Care for implant fabrication and drug delivery system manufacturing. The polymer backbone is a nominal 70:30 molar ratio poly(L-lactide-co-D,L-lactide) in which the D,L-lactide comonomer creates sufficient stereochemical irregularity to suppress crystallization under ordinary melt or solvent processing. Differential scanning calorimetry using ISO 11357-2:2020 with a second-heating ramp of 10 K/min shows a single glass transition at 55–60 °C and no first-order melting endotherm, which is the primary thermal difference from semi-crystalline poly(L-lactide) homopolymers that display a melting signal near 170–180 °C.

The designation S identifies the standard release grade within the LR 700-series, with medical-grade quality management and regulatory documentation appropriate for implantable components. Because the resin is amorphous, stress relaxation and solvent penetration differ from crystalline PLLA. This distinction is relevant when selecting a resorption profile for soft-tissue fixation, orthopedic interference screws, urologic components, or drug-matrix applications. The raw polymer falls within the scope of ISO 13781:2017 for poly(lactide) resin properties and fabricated forms, and lot-specific certificates of analysis should be obtained for each manufacturing campaign.

Release specifications are controlled by dilute-solution viscosity and residual chemistry rather than melt flow rate. The following profile summarizes typical manufacturer release limits, which should be confirmed against the lot certificate before processing.

What Limits Processing Temperature Above the Glass Transition?

Thermal processing requires rigorous drying because the polyester backbone undergoes hydrolysis when residual moisture exceeds the manufacturer’s target. A vacuum drying step at 80 °C under 25 mbar absolute for 4–8 h typically reduces water to ≤ 0.05 wt% before compounding. Desiccant-bed dryers with a dew point ≤ -40 °C and a dry-nitrogen purge are used for continuous hopper supply in cleanrooms. Moisture remaining above 0.05 wt% accelerates molecular-weight loss at melt temperature, producing a viscosity reduction that appears as a drop in measured inherent viscosity after compounding or molding.

In a co-rotating twin-screw extruder with 40:1 L/D and segmented screw elements, zone temperatures are typically set between 165 °C and 190 °C from feed to die, with a screw speed of 150–300 min⁻¹. A melt temperature above 200 °C raises the rate of random chain scission and formation of lactide monomer, shifting the molecular-weight distribution toward lower molar mass. Thermogravimetric analysis under nitrogen at 10 K/min in accordance with ISO 11358-1:2022 typically places the onset of thermal decomposition for 70:30 L/DL-lactide copolymers near 250 °C, but viscosity-loss kinetics are already measurable below this onset, so barrel residence time should remain below 120 s.

Production-scale compounding with radiopaque fillers such as 10–20 wt% submicron barium sulfate or iodine-based contrast media requires separate side-feeding after polymer melting. Filler addition raises melt viscosity, observed as torque increase on 25 mm co-rotating extruders. Barrel temperature should be increased by 5–10 °C only after the filler feed zone, and screw speed should be reduced before increasing temperature to limit hydrolytic chain scission. High-shear kneading blocks should be minimized because local temperature excursions in this amorphous grade can narrow the molar-mass distribution and generate oligomeric fractions that migrate during drug-elution testing.

Injection molding with a reciprocating screw of 20:1 to 25:1 L/D and clamp force from 250 kN to 600 kN for small implant components is operated with barrel temperatures of 170–190 °C and mold temperatures of 15–30 °C. The amorphous morphology reduces post-mold shrinkage anisotropy relative to semi-crystalline PLLA because no slow spherulitic crystallization occurs after ejection. Dimensional inspection after conditioning at 23 °C/50% RH for 48 h per ISO 291:2008 is used to confirm part stability before final assembly.

When solvent casting is selected for thin film or drug-eluting matrices

For solvent-cast drug-eluting matrices, LR 704 S is dissolved at 5–15 wt% in dichloromethane or chloroform; tetrahydrofuran and dioxane may be used where lower-boiling solvents are required. The solution is filtered through 0.2 µm PTFE or polypropylene filters before casting onto release liners or coating onto a mandrel. Residual solvent removal is governed by the final device’s ISO 10993-18:2020 chemical characterization data and must meet the applicable ICH Q3C Class 2 limit for methylene chloride of 600 ppm in parenteral or dermal products unless device-specific justification is filed.

Drug-loaded matrices are typically prepared by dispersing or co-dissolving the active pharmaceutical ingredient in the polymer solution. In vitro release data from 70:30 L/DL-lactide copolymers indicate biphasic release: an initial diffusion-controlled phase followed by a degradation-erosion phase. The Korsmeyer-Peppas exponent for thin, monolithic films frequently lies between 0.45 and 0.89, indicating non-Fickian transport once the glass transition falls below the test temperature of 37 °C due to plasticization by water and drug. Acidic degradation products from bulk hydrolysis lower the matrix pH; this autocatalysis is stronger in thick devices than in films because the diffusion path length for soluble oligomers is longer.

Amorphous resorption behavior and lack of crystalline debris relative to homopolymeric PLLA

The 30 mol% D,L-lactide comonomer prevents formation of lamellar crystallites, so hydrolytic degradation proceeds more uniformly through the bulk than in semi-crystalline PLLA. In phosphate-buffered saline at 37 °C and pH 7.4, 70:30 L/DL-lactide copolymers generally show mass-loss lag after 4–6 weeks, with significant molecular-weight reduction occurring before mass loss; semi-crystalline PLLA retains physical form for periods exceeding 24 months. The absence of crystalline regions also reduces the release of crystalline particulate fragments sometimes reported with slowly degrading PLLA implants. Published literature reports that 70:30 L/DL-lactide films lose approximately 50% of their initial mass between 6 months and 12 months, while film thickness and vascularity modify this response in vivo.

Compared with 50:50 poly(D,L-lactide-co-glycolide), LR 704 S contains no glycolide unit; the absence of glycolic acid blocks lowers initial acid burst and shifts the erosion period later. This makes LR 704 S suitable where longer mechanical retention of 12–18 months is desired, such as in certain orthopedic fixation or urologic implants, whereas glycolide-containing copolymers are selected for shorter depot delivery systems. However, the more hydrophobic lactide-only backbone reduces water permeability and may slow release of hydrophilic drugs relative to 50:50 PLGA.

The reference comparisons are drawn from manufacturer technical data sheets and peer-reviewed degradation studies; lot-specific variation and device geometry should be verified independently. Published data for the exact post-processing mechanical properties of this specific grade configuration is limited, so device-level testing is required before design verification.

Interactions with terminal sterilization and regulatory chemical characterization

LR 704 S is supplied non-sterile and must be terminal-sterilized after forming. Ethylene oxide sterilization is frequently used at chamber temperatures of 45–50 °C and relative humidity of 40–60%, followed by aeration until residuals meet ISO 10993-7:2008 limits for ethylene oxide and ethylene chlorohydrin. Gamma irradiation at 25–40 kGy reduces molecular weight by chain scission; the resulting reduction in inherent viscosity can exceed 10–20% depending on dose rate, packaging oxygen content, and pre-irradiation molar mass. Electron-beam irradiation at equivalent doses may produce a lower temperature excursion but similar radical-mediated chain scission. For load-bearing devices, the design margin should account for the post-sterilization decrease in viscosity rather than relying solely on pre-sterilization mechanical data.

Chemical characterization under ISO 10993-18:2020 should include residual lactide, residual solvent, catalyst residues, oligomers, and sterilization by-products. Biological evaluation follows ISO 10993-1:2023 and typically includes cytotoxicity, sensitization, and irritation endpoints; device-specific implants may require subacute or subchronic implantation studies under ISO 10993-6:2016. The polymer is manufactured under a quality management system aligned with EN ISO 13485:2016, and the supplier provides change notification and regulatory support documentation for medical device master files.

Final device functional testing should include tensile, flexural, or compressive testing under ASTM D638-14 for plastic specimens or appropriate implant-specific standards, after conditioning at 23 °C/50% RH for 48 h. Mechanical properties for amorphous 70:30 L/DL-lactide are generally lower in modulus than semi-crystalline PLLA homopolymer; published values for tensile modulus fall in the range of 2.5–3.5 GPa and tensile strength in the range of 40–60 MPa. Because the material is amorphous, these values are strongly influenced by test rate, temperature, and residual moisture; uncontrolled specimen preparation methods in literature make independent confirmatory testing essential.

Autocatalytic degradation and device geometry

Device thickness governs the autocatalytic degradation of LR 704 S because carboxyl-terminal degradation products diffuse out of thin films but accumulate in the interior of thick injection-molded implants. In a cylinder or screw geometry above 2 mm wall thickness, a pH gradient develops between the acid-rich core and the more neutral surface, producing heterogeneous degradation and a hollow-core appearance at late stages. Size-exclusion chromatography with multi-angle light scattering detects molar-mass reduction before mass loss; in 0.15 M phosphate-buffered saline at pH 7.4 and 37 °C, weight-average molar mass typically falls by 50% within the first few weeks while dry mass remains nearly constant. This latent period is a critical design parameter for resorbable fixation devices: mechanical strength may decline before visual resorption is apparent.

End-group capping or blending with buffering excipients may slow autocatalysis, but such modifications also shift release kinetics and the thermal processing window. The acid-functional polymer should not be compounded with amine-based nucleophilic additives because amidation or transesterification at processing temperatures can narrow the molar-mass distribution and alter viscosity in an uncontrolled manner. Similarly, prolonged contact with alkaline saline cleaning solutions should be avoided before final packaging because surface hydrolysis increases amorphous surface polarity and alters cell adhesion in subsequent in vitro assays.

Storage stability is optimized by keeping the resin in tightly sealed, low-permeability containers under inert gas at -20 °C to -25 °C for long-term storage or 2–8 °C for short-term transfer. Before opening, containers should be equilibrated to ambient temperature to prevent moisture condensation on cold polymer surfaces. Any open container should be returned to dry storage within 24 h and reprocessed by vacuum drying before melt compounding. These controls are necessary because the same ester bond lability that enables bioresorption also makes the moisture-exposed resin susceptible to progressive molecular-weight loss during warehouse storage in uncontrolled tropical environments.